The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
about
KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
P2860
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@ast
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@en
type
label
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@ast
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@en
prefLabel
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@ast
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@en
P2093
P2860
P356
P1433
P1476
The pan-HER family tyrosine ki ...... in non-small cell lung cancer
@en
P2093
Hiroyasu Kaneda
Isamu Okamoto
Kaoru Tanaka
Kazuhiko Nakagawa
Kazuto Nishio
Keita Kudo
Kimio Yonesaka
Masayuki Takeda
Satomi Nishida
Takayuki Takahama
P2860
P304
33602-33611
P356
10.18632/ONCOTARGET.5286
P407
P577
2015-09-15T00:00:00Z